Farther Finance Advisors’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$37.5K Buy
681
+156
+30% +$6.38K ﹤0.01% 3484
2026
Q1
$17.6K Buy
525
+143
+37% +$4.26K ﹤0.01% 3748
2025
Q4
$11.4K Buy
382
+122
+47% +$3.98K ﹤0.01% 3828
2025
Q3
$9.39K Buy
260
+30
+13% +$988 ﹤0.01% 3466
2025
Q2
$8.27K Sell
230
-332
-59% -$12.4K ﹤0.01% 3170
2025
Q1
$21.2K Buy
562
+359
+177% +$12.1K ﹤0.01% 2361
2024
Q4
$6.11K Sell
203
-28
-12% -$804 ﹤0.01% 2579
2024
Q3
$5.4K Buy
231
+18
+8% +$393 ﹤0.01% 2615
2024
Q2
$3.86K Buy
213
+26
+14% +$415 ﹤0.01% 2510
2024
Q1
$2.76K Buy
187
+27
+17% +$430 ﹤0.01% 2356
2023
Q4
$2.73K Buy
160
+60
+60% +$697 ﹤0.01% 2293
2023
Q3
$836 Buy
+100
New +$1.39K ﹤0.01% 2123
2023
Q1
Sell
-95
Closed -$1.12K 2422
2022
Q4
$1.12K Buy
+95
New +$690 ﹤0.01% 1623

Other funds holding TGTX

Farther Finance Advisors's TGTX Position: Q2 2026 in Review

Farther Finance Advisors increased its TG Therapeutics (TGTX) stake by 30% in Q2 2026, buying an estimated $6.38K and bringing the position to 681 shares worth $37.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3484.

Farther Finance Advisors first reported a position in TGTX in Q4 2022 and has held it in 13 quarters since. 78 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Farther Finance Advisors held 681 shares of TG Therapeutics worth $37.5K as of Q2 2026.
  • Farther Finance Advisors bought 156 TG Therapeutics shares in Q2 2026, an estimated $6.38K.
  • TG Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #3484 holding.
  • Farther Finance Advisors first reported a position in TG Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • 78 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.